Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Treatment Options in Neurology
Erschienen in: Current Treatment Options in Neurology 3/2013

01.06.2013 | NEUROIMMUNOLOGY (RP LISAK, SECTION EDITOR)

Chronic Inflammatory Demyelinating Polyneuropathy

verfasst von: Mazen M. Dimachkie, M.D., Richard J. Barohn, M.D.

Erschienen in: Current Treatment Options in Neurology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Opinion statement

Chronic Inflammatory polyneuropathies are an important group of neuromuscular disorders that present chronically and progress over more than 8 weeks, being referred to as chronic inflammatory demyelinating polyneuropathy (CIDP). Despite tremendous progress in elucidating disease pathogenesis, the exact triggering event remains unknown. Our knowledge regarding diagnosis and management of CIDP and its variants continues to expand, resulting in improved opportunities for identification and treatment. Most clinical neurologists will be involved in the management of patients with these disorders, and should be familiar with available therapies for CIDP. We review the distinctive clinical, laboratory, and electro-diagnostic features that aid in diagnosis. We emphasize the importance of clinical patterns that define treatment responsiveness and the most appropriate therapies in order to improve prognosis.
Literatur
1.
Dyck PJ, Oviatt KF, Lambert EH. Intensive evaluation of referred unclassified neuropathies yields improved diagnosis. Ann Neurol. 1981;10(3):222–6.PubMedCrossRef
2.
Barohn RJ. Approach to peripheral neuropathy and neuronopathy. Semin Neurol. 1998;18(1):7–18.PubMedCrossRef
3.
Khan S, Wolfe G, Nascimento O, Pasnoor M, et al. North American and South America (NA-SA) Neuropathy project (abstract). Neurology. 2006;66:A84.CrossRef
4.
Pasnoor M, Nascimento O, Trivedi J, Wolfe GI, Nations S, Herbelin L, et al. North America and South America (NA-SA) Neuropathy Project. International Journal of Neuroscience 2013. doi:10.​3109/​00207454.​2013.​782026
5.
Laughlin RS, Dyck PJ, Melton 3rd LJ, Leibson C, Ransom J, Dyck PJ. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology. 2009;73(1):39–45.PubMedCrossRef
6.
McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain. 1987;110:1617–30.PubMedCrossRef
7.
Holzbauer SM, DeVries AS, Sejvar JJ, et al. Epidemiologic investigation of immune-mediated polyradiculoneuropathy among abattoir workers exposed to porcine brain. PLoS One. 2010;5(3):e9782.PubMedCrossRef
8.
Dyck PJ, Arnason BG. Chronic inflammatory demyelinating polyradiculoneuropathy. In: Dyck PJ, Thomas PK, Lambert EH, Bunge R, editors. Peripheral neuropathy. 2nd ed. Philadelphia: WB Saunders; 1984. p. 2101–14.
9.
Austin JH. Recurrent polyneuropathies and their corticosteroids treatment. Brain. 1958;8:157–92.CrossRef
10.
Viala K, Maisonobe T, Stojkovic T, Koutlidis R, Ayrignac X, Musset L, et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2010;15(1):50–6.PubMedCrossRef
11.
Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology. 1997;48:321–8.PubMedCrossRef
12.
Sabatelli M, Madia F, Mignogna T, Lippi G, Quaranta L, Tonali P. Pure motor chronic inflammatory demyelinating polyneuropathy. J Neurol. 2001;248:772–7.PubMedCrossRef
13.
Dionne A, Nicolle MW, Hahn AF. Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy. Muscle Nerve. 2010;41(2):202–7.PubMed
14.
Ruts L, Drenthen J, Jacobs BC, van Doorn PA, Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology. 2010;74(21):1680–6.PubMedCrossRef
15.
Hughes R, Sanders E, Hall S, Atkinson P, Colchester A, Payan P. Subacute idiopathic demyelinating polyradiculoneuropathy. Arch Neurol. 1992;49:612–6.PubMedCrossRef
16.
Oh SJ. Subacute demyelinating polyneuropathy responding to corticosteroid treatment. Arch Neurol. 1978;35:509–16.PubMedCrossRef
17.
Oh SJ, Kurokawa K, de Almeida DF, Ryan HF, Claussen GC. Subacute inflammatory demyelinating polyneuropathy. Neurology. 2003;61:1507–12.PubMedCrossRef
18.
Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve. 2001;24:311–24.PubMedCrossRef
19.
Koller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med. 2005;352:1343–56.PubMedCrossRef
20.
Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn RJ. Distal acquired demyelinating symmetric (DADS) neuropathy. Neurology. 2000;54:615–20.PubMedCrossRef
21.
Saperstein DS, Amato AA, Wolfe GI, Katz JS, Nations SP, Jackson CE, et al. Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome. Muscle Nerve. 1999;22:560–6.PubMedCrossRef
22.
Viala K, Renié L, Maisonobe T, et al. Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain. 2004;127:2010–7.PubMedCrossRef
23.
Verschueren A, Azulay JP, Attarian S, et al. Lewis-Sumner syndrome and multifocal motor neuropathy. Muscle Nerve. 2004;31:88–94.CrossRef
24.
Alaedini A, Sanders HW, Hays AP, Latov N. Antigangioside antibodies in multifocal acquired sensory and motor neuropathy. Arch Neurol. 2003;60:42–6.PubMedCrossRef
25.
Oh SJ, Claussen GC, Dae SK. Motor and sensory demyelinating mononeuropathy multiplex (multifocal motor and sensory demyelinating neuropathy): a separate variant of chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 1997;2:362–9.PubMed
26.
Gorson KC, Ropper AH, Weinberg DH. Upper limb predominant, multifocal chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 1999;22:758–65.PubMedCrossRef
27.
Thomas PK, Claus D, Jaspert A, Workman JM, King RH, Larner AJ, et al. Focal upper limb demyelinating neuropathy. Brain. 1996;119:765–74.PubMedCrossRef
28.
Lewis RA, Sumner AJ, Brown MJ, Asbury AK. Multifocal demyelinating neuropathy with persistent conduction block. Neurology. 1982;32:958–64.PubMedCrossRef
29.
Gibbels E, Behse F, Kentenich M, Haupt WF. Chronic multifocal neuropathy with persistent conduction block (Lewis- Sumner syndrome). A clinico-morphologic study of two further cases with review of the literature. Clin Neuropathol. 1993;12:343–52.PubMed
30.
Nukada H, Pollock M, Haas LF. Is ischemia implicated in chronic multifocal demyelinating neuropathy? Neurology. 1989;39:106–10.PubMedCrossRef
31.
Dyck PJ, Lais AC, Otha M, Bastron JA, Okasaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc. 1975;50:621–37.PubMed
32.
Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol. 1989;46:878–84.PubMedCrossRef
33.
Dalakas M, Houff SA, Engel WK, Madden DL, Sever JL. CSF "monoclonal" bands in chronic relapsing polyneuropathy. Neurology. 1980;30:864–7.PubMedCrossRef
34.
Bromberg MB. Comparison of electrodiagnostic criteria for primary demyelination in chronic polyneuropathy. Muscle Nerve. 1991;14:968–76.PubMedCrossRef
35.
Thaisetthawatkul P, Logigian EL, Herrmann DN. Dispersion of the distal compound muscle action potential as a diagnostic criterion for chronic inflammatory demyelinating polyneuropathy. Neurology. 2002;59(10):1526–32.PubMedCrossRef
36.
Van den Bergh PY, Pieret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2004;29(4):565–74.PubMedCrossRef
37.
Dimachkie MM, Anderson HS, Gronseth GS, Herbelin L, Pasnoor M, McVey AL, et al. How common is sural nerve sparing in chronic inflammatory demyelinating polyneuropathy? 2008 meeting of the Inflammatory Neuropathy Consortium. JPNS. 2008;13:166a.
38.
Koski CL, Baumgarten M, Magder LS, Barohn RJ, Goldstein J, Graves M, et al. Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2009;277(1-2):1–8.PubMedCrossRef
39.••
Van den Bergh PY, Hadden RD, Bouche P, Cornblath DR, Hahn A, Illa I, et al. European Federation of Neurological Societies; Peripheral Nerve Society European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol. 2010;17(3):356–63. This report expands the electrophysiologic criteria and clinical phenotypes of CIDP. It also updates treatment recommendations.PubMedCrossRef
40.
Rajabally YA, Samarasekera S. Electrophysiological sensory demyelination in typical chronic inflammatory demyelinating polyneuropathy. Eur J Neurol. 2010;17(7):939–44.PubMedCrossRef
41.
Molenaar DS, Vermeulen M, de Haan R. Diagnostic value of sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 1998;64:84–9.PubMedCrossRef
42.
Bosboom WM, Van den Berg LH, Franssen H, et al. Diagnostic value of sural demyelination in chronic inflammatory demyelinating polyneuropathy. Brain. 2001;124:2427–38.PubMedCrossRef
43.
Sommer C, Koch S, Lammens M, Gabreels-Festen A, Stoll G, Toyka KV. Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP. Neurology. 2005;65(12):1924–9.PubMedCrossRef
44.
England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, Cohen JA, et al. American Academy of Neurology. Practice Parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology. 2009;72(2):177–84.PubMedCrossRef
45.
Hafer-Macko CE, Sheikh KA, Li CY, Ho TW, Cornblath DR, McKhann GM, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol. 1996;39(5):625–35.PubMedCrossRef
46.
Matsummuro K, Izumo S, Umehara F, Osame M. Chronic inflammatory demyelinating polyneuropathy: Histological and immunopathological studies in biopsied sural nerves. J Neurol Sci. 1994;127:170–8.CrossRef
47.
Kieseier BC, Tani M, Mahad D, Oka N, Ho T, Woodrofe N, et al. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain. 2002;125:823–34.PubMedCrossRef
48.
Leppert D, Hughes P, Huber S, Erne B, Grygar C, Said G, et al. Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy. Neurology. 1999;53:62–70.PubMedCrossRef
49.
Yan WX, Taylor J, Andrias-Kauba S, Pollard JD. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol. 2000;47:765–75.PubMedCrossRef
50.
Koski CL, Sanders ME, Swoveland PT, et al. Activation of terminal components of complement in patients with Guillain-Barre syndrome and other demyelinating neuropathies. J Clin Invest. 1987;80:1492–7.PubMedCrossRef
51.
Hays AP, Lee SS, Latov N. Immune reactive C3d on the surface of myelin sheaths in neuropathy. J Neuroimmunol. 1988;18:231–44.PubMedCrossRef
52.
Allen D, Giannopoulos K, Gray I, Gregson N, Makowska A, Pritchard J, et al. Antibodies to peripheral nerve myelin proteins in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2005;10(2):174–80.PubMedCrossRef
53.
De Luca G, Lugaresi A, Iarlori C, et al. Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol. 1999;95:190–4.PubMedCrossRef
54.
Chi LJ, Wang HB, Wang WZ. Impairment of circulating CD4 + CD25+ regulatory T cells in patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2008;13:54–63.PubMedCrossRef
55.
Nimmerjahn F, Lünemann JD. Expression and function of the inhibitory Fcγ-receptor in CIDP. J Peripher Nerv Syst. 2011;16 Suppl 1:41–4.PubMedCrossRef
56.
Tackenberg B, Jelcic I, Baerenwaldt A, Oertel WH, Sommer N, Nimmerjahn F, et al. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A. 2009;106:4788–92.PubMedCrossRef
57.
Comi C, Gaviani P, Leone M, Ferretti M, Castelli L, Mesturini R, et al. Fas-mediated T-cell apoptosis is impaired in patients with chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 2006;11(1):53–60.PubMedCrossRef
58.
Amato AA, Barohn RJ, Sahenk Z, Tushka PJ, Mendell JR. Polyneuropathy complicating bone marrow transplantation. Neurology. 1993;43:1513–8.PubMedCrossRef
59.
Rechthand E, Cornblath DR, Stern BJ, Meyerhoff JO. Chronic demyelinating polyneuropathy in systemic lupus erythematosus. Neurology. 1984;34:1375–7.PubMedCrossRef
60.
Romanick-Schmiedl S, Kiprov DD, Chalmers AC, Miller RG. Extraneural manifestations of chronic inflammatory demyelinating polyradiculoneuropathy. Am J Med. 1990;89:531–4.PubMedCrossRef
61.
Stewart JD, McKelvey R, Durcan L, Carpenter S, Karpati G. Chronic inflammatory demyelinating polyneuropathy (CIDP) in diabetics. J Neurol Sci. 1996;142:59–64.PubMedCrossRef
62.
Taylor BV, Wijdicks EFM, Poterucha JJ, Weinser RH. Chronic inflammatory demyelinating polyneuropathy complicating liver transplantation. Ann Neurol. 1995;38:828–31.PubMedCrossRef
63.
Dyck PJ, Swanson CJ, Low PA, Bartleson JD, Lambert EH. Prednisone-responsive hereditary motor and sensory neuropathy. Mayo Clin Proc. 1982;57:239–46.PubMed
64.
Mendell JR, Kolkin S, Kissel JT, Weiss KL, Chakeres DW, Rammohan KW. Evidence for central nervous system demyelination in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 1987;37(8):1291–4.PubMedCrossRef
65.
Ad Hoc Subcommittee of the American Academy of Neurology. AIDS Task Force. Research criteria for diagnosis chronic inflammatory demyelinating polyneuropathy. Neurology. 1991;41:617–8.CrossRef
66.
Ginsberg L, Malik O, Kenton AR, Sharp D, Muddle JR, Davis MB, et al. Coexistent hereditary and inflammatory neuropathy. Brain. 2004;127(Pt 1):193–202.PubMedCrossRef
67.
Jann S, Bramerio MA, Facchetti D, Sterzi R. Intravenous immunoglobulin is effective in patients with diabetes and with chronic inflammatory demyelinating polyneuropathy: long term follow-up. J Neurol Neurosurg Psychiatry. 2009;80(1):70–3.PubMedCrossRef
68.
Kalita J, Misra UK, Yadav RK. A comparative study of chronic inflammatory demyelinating polyradiculoneuropathy with and without diabetes mellitus. Eur J Neurol. 2007;14(6):638–43.PubMedCrossRef
69.
Stübgen JP. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve. 2008;37(3):281–92.PubMedCrossRef
70.
Kundi S, Barohn R, McVey A, Dimachkie M, Pasnoor M, Herbelin L. Tacrolimus and Relapsing-Remitting CIDP: a case report. J Clin Neuromuscul Dis. 2010;11(3):9.
71.
Wilson JR, Conwit RA, Eidelman BH, Starzl T, Abu-Elmagd K. Sensorimotor neuropathy resembling CIDP in patients receiving FK506. Muscle Nerve. 1994;17(5):528–32.PubMedCrossRef
72.
Echaniz-Laguna A, Battaglia F, Ellero B, Mohr M, Jaeck D. Chronic inflammatory demyelinating polyradiculoneuropathy in patients with liver transplantation. Muscle Nerve. 2004;30(4):501–4.PubMedCrossRef
73.
Labate A, Morelli M, Palamara G, Pirritano D, Quattrone A. Tacrolimus-induced polyneuropathy after heart transplantation. Clin Neuropharmacol. 2010;33(3):161–2.PubMedCrossRef
74.
Rotta FT, Sussman AT, Bradley WG, Ayyar DR, Sharma KR, Shebert RT. The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci. 2000;173:129–39.PubMedCrossRef
75.
Kelly JJ, Kyle RA, Miles JM, Dyck PJ. Osteosclerotic myeloma and peripheral neuropathy. Neurology. 1983;33(2):202–10.PubMedCrossRef
76.
Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Therneau TM, Larson DR, et al. POEMS syndrome: definitions and long-term outcome. Blood. 2003;101(7):2496–506.PubMedCrossRef
77.
Watanabe O, Maruyama I, Arimura K, Kitajima I, Arimura H, Hanatani M, et al. Overproduction of vascular endothelial growth factor - Vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve. 1998;21(11):1390–7.PubMedCrossRef
78.
Watanabe O, Arimura K, Kitajima I, Osame M, Maruyama I. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet. 1996;347(9002):702.PubMedCrossRef
79.
Dyck PJ, O'Brien PC, Oviatt KF, Dinapoli RP, Daube JR, Bartleson JD, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 1982;11:136–41.PubMedCrossRef
80.
Dyck PJ, Daube J, O'Brien P, Pineda A, Low PA, Windebank AJ, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986;314:461–5.PubMedCrossRef
81.
Hahn AF, Bolton CF, Pillay N, Chalk C, Benstead T, Bril V, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, sham-controlled, cross-over study. Brain. 1996;119:1055–66.PubMedCrossRef
82.
Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, cross-over study. Brain. 1996;119:1067–77.PubMedCrossRef
83.
Mendell JR, Barohn RJ, Freimer ML, Kissel JT, King W, Nagaraja HN, et al. Working group on peripheral neuropathy: randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 2001;56:445–9.PubMedCrossRef
84.
Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, et al. ICE Study Group. Intravenous immune globulin (10 % caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomized placebo-controlled trial. Lancet Neurol. 2008;7(2):136–44.PubMedCrossRef
85.
Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50:195–201.PubMedCrossRef
86.
Lopate G, Pestronk A, Al-Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol. 2005;62:249–54.PubMedCrossRef
87.
Muley SA, Kelkar P, Parry GJ. Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids. Arch Neurol. 2008;65(11):1460–4.PubMedCrossRef
88.
Harbo T, Andersen H, Jakobsen J. Acute motor response following a single IVIG treatment course in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2009;39(4):439–47.PubMedCrossRef
89.
Bril V, Banach M, Dalakas MC, Deng C, Donofrio P, Hanna K, et al. ICE Study Group. Electrophysiologic correlations with clinical outcomes in CIDP. Muscle Nerve. 2010;42(4):492–7.PubMedCrossRef
90.
Lee DH, Linker RA, Paulus W, Schneider-Gold C, Chan A, Gold R. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2008;37(3):406–9.PubMedCrossRef
91.
Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006;313(5787):670–3.PubMedCrossRef
92.
Dyck PJ, O'Brien PC, Swanson C, et al. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology. 1985;35:1173–6.PubMedCrossRef
93.
Hodgkinson SJ, Pollard JD, McLeod JG. Cyclosporine A in the treatment of chronic demyelinating polyradiculopathy. J Neurol Neurosurg Psychiatry. 1990;53:327–30.PubMedCrossRef
94.
Barnett MH, Pollard JD, Davies L, McLeod JG. Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 1998;21(4):454–60.PubMedCrossRef
95.
Koski CL. Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy: pathogenesis and treatment. Semin Neurol. 1994;14:123–30.PubMedCrossRef
96.
Good JL, Chehrenama M, Mayer RF, Koski CL. Pulsed cyclophosphamide in chronic inflammatory demyelinating polyneuropathy. Neurology. 1998;51:1735–8.PubMedCrossRef
97.
Brannagan TH, Pradham A, Heiman-Patterson T, et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology. 2002;58:1856–8.PubMedCrossRef
98.
Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology. 2001;56:94–6.PubMedCrossRef
99.
Mowzoon N, Sussman A, Bradley WG. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy, and inclusion body myositis. J Neurol Sci. 2001;185(2):119–22.PubMedCrossRef
100.
Gorson KC, Amato AA, Ropper AH. Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology. 2004;63:715–7.PubMedCrossRef
101.
Sabatelli M, Mignona T, Lippi G, Milone M, Lazzaro VD, Tonali P. Interferon-alpha may benefit steroid unresponsive chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 1995;58:638–9.PubMedCrossRef
102.
Choudhary PP, Thompson N, Hughes RAC. Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol. 1995;242:252–3.PubMedCrossRef
103.
Gorson KC, Ropper AH, Clark BD, Dew RB, Simovic D, Allam G. Treatment of chronic inflammatory demyelinating polyneuropathy with interferon alpha 2a. Neurology. 1998;50:84–7.PubMedCrossRef
104.
Hadden RDM, Sharrack B, Bensa S, Soudain SE, Hughes RAC. Randomized trial of interferon B-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 1999;53:57–61.PubMedCrossRef
105.
Kuntzer T, Radziwill AJ, Lettry-Trouillat R, et al. Interferon-B1a in chronic inflammatory demyelinating polyneuropathy. Neurology. 1999;53:1364–5.PubMedCrossRef
106.
Pavesi G, Cattaneo L, Marbini A, Gemignani F, Mancia D. Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating neuropathy. J Neurol. 2002;249:777–9.PubMedCrossRef
107.
Vallat JM, Hahn AF, Leger JM, et al. Interferon beta 1a as an investigational treatment for CIDP. Neurology. 2003;60 Suppl 3:S23–8.PubMedCrossRef
108.
Fialho D, Chan YC, Allen DC, Reilly MM, Hughes RA. Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate. J Neurol Neurosurg Psychiatry. 2006;77:544–7.PubMedCrossRef
109.
RMC Trial Group. Randomized controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicenter study. Lancet Neurol. 2009;8(2):158–64.CrossRef
110.
Hughes RA, Gorson KC, Cros D, Griffin J, Pollard J, Vallat JM, et al. Avonex CIDP Study Group. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 2010;74(8):651–7.PubMedCrossRef
111.
Niermeijer JM, Eurelings M, Lokhorst H, Franssen H, Fijnheer R, Wokke JH, et al. Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy. Neurology. 2006;67(11):2076–9.PubMedCrossRef
112.
Gladstone DE, Prestrud AA, Brannagan III TH. High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 2005;10(1):11–6.PubMedCrossRef
113.
Benedetti L, Briani C, Franciotta D, Fazio R, Paolasso I, Comi C, et al. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry. 2011;82(3):306–8.PubMedCrossRef
114.
Marsh EA, Hirst CL, Llewelyn JG, Cossburn MD, Reilly MM, Krishnan A, et al. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J Neurol. 2010;257(6):913–9.PubMedCrossRef
115.
Gordon PH, Brannagan TH, Latov N. Neurological manifestations of paraproteinemia and cryoglobulinemia. In: Aminoff MJ, Goetz CG, editors. Handbook of clinical neurology. Science.: Elsevier; 1998. p. 431–59.
116.
Oyama R MD, Sufit MDY, Loh MDL, Statkute MDK, Yaung RNK, Quigley RNE, et al. Nonmyeloablative autologous hematopoietic stem cell transplantation for refractory CIDPY. Neurology. 2007;69:1802–3.PubMedCrossRef
117.
Kuwabara S, Misawa S, Kanai K, Kikkawa Y, Nishimura M, Nakaseko C, et al. Autologous peripheral blood stem cell transplantation for POEMS syndrome. Neurology. 2006;66(1):105–7.PubMedCrossRef
118.
Mahdi-Rogers M, Kazmi M, Ferner R, Hughes RA, Renaud S, Steck AJ, et al. Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy. J Peripher Nerv Syst. 2009;14(2):118–24.PubMedCrossRef
119.
Kuwabara S, Misawa S, Kanai K, Sawai S, Hattori T, Nishimura M, et al. Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome. J Neurol Neurosurg Psychiatry. 2008;79(11):1255–7.PubMedCrossRef
120.
Hughes RA, Bouche P, Cornblath DR, Evers E, Hadden RD, Hahn A, et al. In: European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol. 2006;13(4):326–32.PubMedCrossRef
121.
Bouchard C, Lacroix C, Plante V, Adams D, Chedru F, Guglielmi JM, et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology. 1999;52:498–503.PubMedCrossRef
Metadaten
Titel
Chronic Inflammatory Demyelinating Polyneuropathy
verfasst von
Mazen M. Dimachkie, M.D.
Richard J. Barohn, M.D.
Publikationsdatum
01.06.2013
Verlag
Current Science Inc.
Erschienen in
Current Treatment Options in Neurology / Ausgabe 3/2013
Print ISSN: 1092-8480
Elektronische ISSN: 1534-3138
DOI
https://doi.org/10.1007/s11940-013-0229-6

Weitere Artikel der Ausgabe 3/2013

Current Treatment Options in Neurology 3/2013 Zur Ausgabe

NEURO-ONCOLOGY (NEOPLASMS) (MR ROSENFELD, SECTION EDITOR)

Treatment Options in Newly Diagnosed Glioblastoma

NEURO-ONCOLOGY (NEOPLASMS) (MR ROSENFELD, SECTION EDITOR)

Gliomas in Children

NEURO-ONCOLOGY (NEOPLASMS) (MR ROSENFELD, SECTION EDITOR)

Anaplastic Astrocytoma

MULTIPLE SCLEROSIS AND RELATED DISORDERS (BM SEGAL, SECTION EDITOR)

B-Cell Targeting Agents in the Treatment of Multiple Sclerosis

NEURO-ONCOLOGY (NEOPLASMS) (MR ROSENFELD, SECTION EDITOR)

Anaplastic Oligodendroglioma: Advances and Treatment Options

NEURO-ONCOLOGY (NEOPLASMS) (MR ROSENFELD, SECTION EDITOR)

Anti-Angiogenic Therapy in High-Grade Glioma (Treatment and Toxicity)

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise